Monday, October 18, 2010 (Last Updated: 10/19/2010)
MONDAY, Oct. 18 (HealthDay News) -- Eight types of human papillomavirus (HPV) appear to be responsible for over 90 percent of the world's cervical cancer cases; researchers recommend these eight types be the target for future vaccines and that the three most common high-risk HPV types -- 16, 18, and 45 -- which occur in younger women, should be the focus of type-specific HPV screening. Their findings have been published online Oct. 18 in The Lancet Oncology.
Silvia de Sanjose, M.D., of the Catalan Institute of Oncology in Barcelona, and colleagues examined 10,575 samples of confirmed invasive cervical cancer from women from 38 countries to provide new, broad-ranging data about the worldwide genotype distribution in patients with invasive cervical cancer.
The researchers found 8,977 (85 percent) of the samples positive for HPV DNA, most commonly types 16, 18, 31, 33, 35, 45, 52, and 58. Types 16 and 18 were found in about 71 percent of the invasive cervical cancer cases, and types 16, 18, and 45 were found in about 94 percent of cervical adenocarcinomas. Cancers due to types 16, 18, and 45 presented at an earlier age than did cancers related to other subtypes.
"To our knowledge, this study is the largest assessment of HPV genotypes to date. HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines. Our results also suggest that type-specific high-risk HPV-DNA-based screening tests and protocols should focus on HPV types 16, 18, and 45," the authors write.
The study was funded by unrestricted grants from GlaxoSmithKline Biologicals, Sanofi Pasteur MSD, and Merck. Several of the authors disclosed financial relationships with various pharmaceutical companies.
Hematology & Oncology
OBGYN & Women's Health
Copyright © 2010 HealthDay. All rights reserved.